Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: Doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type

Cancer Research

Volumn 57, Issue 23, 1997, Pages 5309-5319

  Behr, Thomas M ^a   Wulst, Erik ^a   Radetzky, Sven ^a   Blumenthal, Rosalyn D ^b   Dunn, Robert M ^b   Gratz, Stefan ^a   Rave Fränk, Margret ^a   Schmidberger, Heinz ^a   Raue, Friedhelm ^c   Becker, Wolfgang ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b GARDEN STATE CANCER CENTER   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACARBAZINE; DOXORUBICIN; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; CISPLATIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FLUOROURACIL; HUMANS; IMMUNOGLOBULIN G; IODINE RADIOISOTOPES; MICE; MICE, NUDE; RADIOIMMUNOTHERAPY; STREPTOZOCIN; THYROID NEOPLASMS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 14444275786     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. De Vita, V. T., Hellman, S., and Rosenberg, S. A. (eds.). Cancer: Principles and Practice of Oncology, Ed. 5. Philadelphia: Lippincott-Raven, 1997.
2. Raue, F. (ed.). Medullary Thyroid Carcinoma. Berlin: Springer-Verlag, 1992.
3. Pacini, F., Fontanelli, M., Fugazzola, L., Elisei, R., Romei, C., Di Coscio, G., Miccoli, P., and Pinchera, A. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid cancer. J. Clin. Endocrinol. Metab., 78: 826-829, 1994.
4. Bergholm, U., Bergström, R., and Ekbom, A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer (Phila.), 79: 132-138, 1997.
5. Tisell, L. E., Hansson, G., Jansson, S., and Salander, H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery (St. Louis), 99: 60-66, 1986.
6. Tisell, L. E., Dilley, W. G., and Wells, S. A. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery (St. Louis), 119: 34-39, 1996.
7. Samaan, N. A., Schultz, P. N., and Hickey, R. C. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J. Clin. Endocrinol. Metab., 67: 801-808, 1988.
8. van Heerden, J. A., Grand, C. S., Gharib, H., Hay, I. D., and Ilstrup D. M. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid cancer. Ann. Surg., 212: 395-401, 1990.
9. Behr, T. M., Gratz, S., Markus, P. M., Dunn, R. M., Hüfner, M., Becker, H., and Becker, W. Enhanced bilateral somatostatin receptor expression in mediastinal lymph nodes ("chimney sign") in occult metastatic medullary thyroid cancer: a typical sign of tumour manifestation? Eur. J. Nucl. Med., 24: 184-191, 1997.
10. Behr, T. M., Gratz, S., Markus, P. M., Dunn, R. M., Hüfner, M., Schauer, A., Fischer, M., Munz, D. L., Becker, H., and Becker, W. S. Anti-CEA antibodies versus somatostatin-analogs in detection of metastatic medullary thyroid cancer: are CEA and somatostatin-receptor expression prognostic factors? Cancer (Phila.), in press, 1997.
11. Simpson, W. J., Sutcliffe, S. B., and Gospodarowicz, M. K. The thyroid. In: Cox, J. D. (ed.). Moss' Radiation Oncology: Rationale, Technique, Results, Ed. 7, pp. 280-304. St. Louis: Mosby, 1994.
12. 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res., 55 (Suppl.): 5946s-5951s, 1995.
13. 131I-labeled anti-CEA antibodies. J. Nucl. Med., 37: 875-881, 1996.
14. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Siegel, J. A., and Goldenberg, D. M. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J. Nucl. Med., 38: 409-418, 1997.
15. American Type Culture Collection. ATCC Cell Lines and Hybridomas, Ed. 8, p. 174. Rockville, MD: American Type Culture Collection, 1994.
16. Goldenberg, D. M., Witte, S., and Elster, K. A new human tumor serially transplantable in the golden hamster. Transplantation (Baltimore), 4: 760-764, 1966.
17. Behr, T. M., Sharkey, R. M., Sgouros, G., Blumenthal, R. D., Dunn, R. M., Kolbert, K., Griffiths, G., Siegel, J. A., Becker, W. S., and Goldenberg, D. M. Overcoming nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy in a nude mouse model in relation to the internal radiation dosimetry. Cancer (Phila.), in press, 1997.
18. 99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J. Nucl. Med., 36: 430-441, 1995.
19. 99mTc: the role of metabolism and kinetics. Cancer Res., 55 (Suppl.): 5777s-5785s, 1995.
20. Primus, F. J., Newell, K. D., Blue, A., and Goldenberg, D. M. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res., 43: 686-692, 1983.
21. Weadock, K. S., Sharkey, R. M., Varga, D. C., and Goldenberg, D. M. Evaluation of a remote radioiodination system for radioimmunotherapy. J. Nucl. Med., 31: 508-511, 1990.
22. Behr, T. M., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Siegel, J. A., and Goldenberg, D. M. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumors. Cancer Res., 56: 1805-1816, 1996.
23. Behr, T. M., Sharkey, R. M., Juweid, M. E., Blumenthal, R. D., Dunn, R. M., Bair, H. J., Griffiths, G. L., Wolf, F. G., Becker, W. S., and Goldenberg D. M. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res., 55: 3825-3834, 1995.
24. Sharkey, R. M., Motta-Hennessy, C., Pawlyk, D., Siegel, J. A., and Goldenberg, D. M Biodistrihution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonie tumor xenografts. Cancer Res., 50: 2330-2336, 1990.
25. Siegel, J. A., and Stabin, M. G. Absorbed fractions for electrons and β particles in small spheres. J. Nucl. Med., 29: 803, 1988.
26. Hui, T. E., and Poston, J. W. A model of the circulating blood for use in radiation dose calculations. In: Proceedings of the International Conference on Radiation Dosimetry and Safety, pp. 151-168. Taiwan: 1987.
27. Blumenthal, R. D., Sharkey, R. M., Forman, D., Wong, G., Hess, J., and Goldenberg, D. M. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation. Exp. Hematol., 23: 1088-1097, 1995.
28. Greco, W., Bravo, G., and Parsons, J. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev., 47: 331-385, 1995.
29. 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int. J. Rad. Oncol. Biol. Phys., 38: 419-428, 1997.
30. Berenbaum, M. What is synergy? Pharmacol. Rev., 41: 93-141, 1989.
31. Pimm, M. V. Circulating antigen: bad or good for immuno-scintigraphy? Nucl. Med. Biol., 22: 137-145, 1995.
32. Davies, Q., Perkins, A. C., Frier, M., Watson, S., Lalani, E-N., and Symonds, E. M. The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model. Eur. J. Nucl. Med., 24: 206-209, 1997.
33. 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing colon cancer xenografts. Cancer Res., 49: 1587-1594, 1989.
34. Benker, G., and Reinwein, D. Ergebnisse der Chemotherapie des schilddrüsenkarzinoms. Dtsch. Med. Wochenschr., 108: 403-406, 1983.
35. Schlumberger, M., Abdelmoumene, N., Delisle, M. J., Couette, J. E., and Groupe d'Étude des Tumeurs à Calcitonine (GETC). Treatment of advanced medullary thyroid cancer with an alternating combination of 5-FU-streptozotocin and 5-FU-dacarbazine. Br. J. Cancer, 71: 363-365, 1995.
36. Gottlieb, J. A., and Hill, C. S. Chemotherapy of thyroid cancer with Adriamycin. N. Engl. J. Med., 290: 193-197, 1974.
37. Cassady, J. R., Richter, M. P., Piro, A. J., and Jaffe, N. Radiation-Adriamycin interactions: preliminary clinical observations. Cancer (Phila.), 36: 946-949, 1975.
38. Belli, J. A., and Piro, A. J. The interaction between radiation and Adriamycin damage in mammalian cells. Cancer Res., 37: 1624-1630, 1977.
39. Behr. T, M., Goldenberg, D. M., and Becker, W. S. Radioimmunotherapy of solid tumors: a review "of mice and men." Hybdridoma, 16: 101-107, 1997.
40. 2 and metaiodobenzylguanidine. Eur. J. Nucl. Med., 11: 198-200, 1985.
41. Mendelsohn, G., Wells, S. A., Jr., and Baylin, S. B. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. Cancer (Phila.), 54: 657-662, 1984.
42. Busnardo, B., Girelli, M. E., Simioni, N., Nacamulli, D., and Bosetto, E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer (Phila.), 53: 278-285, 1984.
43. Bardiès, M., Bardet, S., Faivre-Chauvet, A., Peltier, P., Douillard, J-Y., Mahé, M., Fiche, M., Lisbona, A., Giacalone, F., Meyer, P., Gautherot, E., Rouvier, E., Barbet, J., and Chatal, J. F. Bispecific antibody and iodine-131-labeled bivalent hapten dosimetry in patients with medullary thyroid or small-cell lung cancer. J. Nucl. Med., 37: 1853-1859, 1996.
44. Zabel, M. and Grzeszkoviek, F. Characterisation of thyroid medullary carcinoma TT cell line. Histol. Histopathol., 12: 283-289, 1997.
45. Sgouros, G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J. Nucl. Med., 34: 689-694, 1993.
46. Blumenthal, R. D., Sharkey, R. M., Natale, A. M., Kashi, R., Wong, G., and Goldenberg, D. M. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res., 54: 142-151, 1994.
47. Blumenthal, R. D., Sharkey, R. M., Gold, D. V., Osorio, L., and Goldenberg, D. M. Multimodal experimental therapy of a s.c. colonic cancer xenograft using radioimmunotherapy (RAIT) and chemotherapy. J. Nucl. Med., 37: 169P, 1996.
48. 131I-labelled monoclonal antibody Po66 and doxorubicin. Cancer Immunol. Immunother., 43: 269-274, 1996.
49. Hall, E. J. Radiobiology for the Radiologist. Philadelphia: J. B. Lippincott Co., 1994.
50. Walden, T. L., Jr., and Farzaneh, N. K. Biochemistry of Ionizing Radiation. New York: Raven Press, 1990.
51. Coleman, C. N., and Turrisi, A. T. Radiation and chemotherapy sensitizers and protectors. Crit. Rev. Oncol. Hematol., 10: 225-252, 1990.
52. Kirichenko, A. V., Rich, T. A., Newman, R. A., and Travis, E. L. Potentiation of murine MCa-4 carcinoma radioresponse by 9-amino-20(S)-camptothecin. Cancer Res., 57: 1929-1933, 1997.
53. Chalandon, Y., Mach, J. P., Pélégrin, A., Folli, S., and Buchegger, F. Combined radioimmunotherapy and chemotherapy of human colon carcinoma xenografted nude mice, advantages and limitations. Anticancer Res., 12: 1131-1140, 1992.
54. Remmenga, S., Colcher, D., Gansow, O., Pippen, G., and Raubitschek, A. Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft. Gynecol. Oncol., 55: 115-122, 1994.
55. Roffler, S. R., Chan, J., and Yeh, M. Y. Potentiation of radioimmunotherapy by inhibition of topoisomerase 1. Cancer Res., 54: 1276-1285, 1994.
56. Corbett, A. H., and Osheroff, N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs. Chem. Res. Toxicol., 6: 585-597, 1993.
57. Donaldson, S. S., Glick, J. M., and Wilbur, J. R. Adriamycin activating a recall phenomenon after radiation therapy. Ann. Intern. Med., 81: 407-408, 1974.
58. Bases, R. E. Modification of the radiation response determined by single-cell technics: actinomycin D. Cancer Res., 19: 1223-1229, 1959.
59. Piro, A. J., Taylor, C. C., and Belli, J. A. Interaction between radiation and drug damage in mammalian cells: I. Delayed expression of actinomycin D/x-ray effects in exponential and plateau phase cells. Radiat. Res., 63: 346-362, 1975.
60. Hellman, S., and Hannon, E. Effects of Adriamycin on the radiation response of murine hematopoietic stem cells. Radiat. Res., 67: 162-167, 1976.
61. Durand, R. E., and LePard, N. E. Tumour blood flow influences combined radiation and doxorubicin treatments. Radiother. Oncol., 42: 171-179, 1997.
62. Yang, K-P., and Samaan, N. A. Lethal efficacy of doxorubicin on human medullary thyroid carcinoma cells in vitro. Anticancer Res., 8: 245-248, 1988.
63. Larsson, R., and Nygren, P. Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein. Cancer Lett., 54: 125-131, 1990.
64. Yang, K-P., Liang, Y-F., and Samaan, N. A. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdr1 gene and low proliferation fraction. Anticancer Res., 11: 1065-1068, 1991.
65. Massart, C., Gibassier, J., Raoul, M., Pourquier, P., Leclech, G., Robert, J., and Lucas, C. Cyclosporin A, verapamil, and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anti-Cancer Drugs, 6: 135-146, 1995.
66. Massart, C., Gibassier, J., Lucas, C., Pourquier, P., and Robert, J. Expression du gène MDR1 dans cinq lignées humaines de cancer médullaire de la thyroïde et réversion de la résistance à la doxorubicine par la ciclosporine A et le vérapamil. Bull. Cancer, 83: 39-45, 1996.